• Component Description
• Eligible Sample
• Interview Setting and Mode of Administration
• Quality Assurance & Quality Control
• Data Processing and Editing
• Analytic Notes
• Codebook
  • SEQN - Respondent sequence number
  • RXDUSE - Taken prescription medicine, past month
  • RXDDRUG - Generic drug name
  • RXDDRGID - Generic drug code
  • RXQSEEN - Medicine container seen by interviewer
  • RXDDAYS - Number of days taken medicine
  • RXDCOUNT - Number of prescription medicines taken

National Health and Nutrition Examination Survey and National Youth Fitness Survey

2012-2012 Data Documentation, Codebook, and Frequencies

NHANES/NNYFS Combined Sample 2012 - Prescription Medications (C_RXQ_RX)

RDC Only Data File: C_RXQ_RX.xpt

First Published: July 2014

Last Revised: NA

Due to disclosure issues, this dataset is not available publicly. Access may be obtained through the NCHS Research Data Center (https://www.cdc.gov/rdc).

Component Description

The Dietary Supplement and Prescription Medication Section (DSQ) of the Sample Person (SP) Questionnaire collects information on 1) dietary supplements, 2) nonprescription antacids, and 3) prescription medications. These questions were asked in the NHANES National Youth Fitness Survey (NNYFS) and of NHANES participants aged 3 to 15 years, during the second year of the 2011–2012 cycle.

The Prescription Medications subsection provides personal interview data on use of prescription medications during a one-month period prior to the survey date.

Eligible Sample

All survey participants aged 3 to 15 years were eligible for the prescription medications questions.

Interview Setting and Mode of Administration

The Prescription Medications (RXQ) subsection was asked, in the home, by trained interviewers using the Computer-Assisted Personal Interviewing (CAPI) system. A proxy provided information for survey participants.

The Interviewer Procedures Manual and Survey Questionnaires can be found on the NNYFS website https://www.cdc.gov/nchs/data/nnyfs/dsq.pdf and NHANES website https://wwwn.cdc.gov/nchs/data/nhanes/2011-2012/questionnaires/dsq.pdf.

Quality Assurance & Quality Control

Data were routinely examined for discrepancies and erroneous entries. All drug names entered by the interviewer were compared to the medication name selected from the database. Review of the 2012 NHANES/NNYFS data found that 91% of all reported drugs were automatically matched to the data collection drug database. The 9%, which were not matched to the drug database, were edited after data collection at NCHS. The most common reasons for a non-match were incorrect spelling of the drug, insufficient detail to identify the drug, or reporting of a nonprescription product that was not in the drug database. Details of the editing process are described below.

Data Processing and Editing

Data Collection Methods

During the household SP interview survey participants are asked if they have taken medications in the past 30 days for which they needed a prescription. Those who answer “yes” are asked to show the interviewer the medication containers of all the products used. For each medication reported, the interviewer enters the product’s complete name from the container into a computer. If no container is available, the interviewer asks the participant to verbally report the name of the medication.

When the interviewer enters the medication name into the computer, the name is automatically matched to a prescription drug database on the computer to identify an exact match or similar text matches (refer below for details on the prescription medication database). The interviewer then selects the best match from a list of possible matches. The original entry of the interviewer and the product selected from the computer list are saved under separate variables for quality control purposes. If an exact match of the medication cannot be found, the interviewer is instructed to select “drug not found on list". Interviewers can record up to 20 prescription medications. Participants are also asked how long they had been taking the medication and the main reason for use.

Prescription Medication Questions Included in this Data Release

• Was any prescription medication taken in the past 30 days?
• Medication name
• Was medication container seen by interviewer?
• How long was medication taken?
• Number of prescription medications taken?

Prescription Medication Database for Data Collection

NCHS used the Lexicon Plus®, a proprietary database of Cerner Multum, Inc. to assist in data collection. The Lexicon Plus® is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For NNYFS and NHANES, the Lexicon Plus® files were modified and uploaded to a laptop computer and incorporated into a search engine for use by interviewers in the field. The computer file is updated at the beginning of each survey year to incorporate changes to the Lexicon Plus® and include products approved and available to the U.S. public in the prior year.

Data Editing

General editing of data:

When a variable was modified globally, as part of the editing process, the third letter in the variable name was changed from a Q (i.e., RXQ) to a D (i.e., RXD). For example, variables that were obtained from an external drug database will have the letter “D” in the third position of the variable name.

Prescription medications incorrectly reported in other subsections of questionnaire:

Prescription antacids that were incorrectly reported in the nonprescription antacid section of the questionnaire were removed from the antacid file and added to the prescription medication file.

Prescription supplements are released in the Dietary Supplements Data File. Some prescription medications were mistakenly recorded in the dietary supplement section. These were removed from that file and added to the prescription medication file. Any prescription dietary supplement that was incorrectly reported in the prescription medication section was removed from the prescription medication section and moved to the dietary supplement section.

Products reported in the prescription medication section that were only available as an over-the-counter product during 2012 were removed from the prescription medication file, except over-the-counter insulin, and products containing pseudoephedrine.

Specific variables and edits:

RXDUSE: Have you taken or used any prescription medicines in the past 30 days?

This variable was the lead-in question to the series of questions on prescription medication use. It accounts for all prescription medications except prescription dietary supplements, which are included in the dietary supplement files (DSQ). This variable was edited and takes into account prescription medications reported in this section as well as prescription medications moved into this file from the dietary supplements or nonprescription antacids sections of the questionnaire.

RXDCOUNT: The number of prescription medicines taken?

This variable was computed at NCHS and represents the total number of prescription medications reported by the participant. The count has been adjusted for all prescription medications moved into and those moved out of the prescription medication section. However, the count is not a comprehensive count of all prescription products used by a participant because prescription dietary supplements are part of the dietary supplement section. There were also participants who reported the use of a prescription medication in the past month (RXDUSE = 1) but did not know the name of the medication (RXDDRUG = 99999). Each product reported as “don’t know” is still included in the total count of prescription medications used under RXDCOUNT. There was no participant who refused to report the name of the medication.

RXQSEEN: Medicine container seen by interviewer?

There was no editing of this variable.

RXDDAYS: For how long have you been taking this medicine?

This variable was created from a two-part (number and unit) question and indicates how long the participant reported taking each prescription medication. Responses were recorded in days, weeks, months, and years. To facilitate analysis, all answers were converted to days using conversion factors of 7 days per week, 30.4 days per month, and 365 days per year.

Drug Database for Data Release:

NCHS used the Lexicon Plus®, a proprietary database of Cerner Multum, Inc. to assist with data editing and release. The December 2012 Multum Lexicon database was used for creating the C_RXQ_RX data. For additional information refer to the RXQ_DRUG documentation.

In accordance with the license agreement, NCHS publications, tabulations, and software applications should cite the Multum Lexicon as the source and basis for the coding and classification of the NHANES drug data.

Creation of additional data release variables:

RXDDRUG: Generic drug name

All reported drug names were converted to a standard generic drug name for data release. For multi-ingredient products, the ingredients are listed in alphabetical order (i.e., Acetaminophen; Codeine).

There were participants who reported the use of a prescription medication but did not know the name of the drug. These entries were coded as don’t know (99999). There were also medications reported with insufficient detail to accurately identify the exact product, but there was some information about the therapeutic class of the drug. These products have been released with Multum’s therapeutic category name followed by “- unspecified” (e.g., anti-infective - unspecified).

RXDDRGID: Generic drug code

Each generic drug name is associated with a unique generic drug code from Multum’s Lexicon Drug Database. Multum's generic drug code is always beginning with a "d". There were some drug names reported by NHANES/NNYFS’ participants that were not found in the Lexicon Drug Database. These have been assigned unique drug codes beginning with an “a.” Unspecified products with known therapeutic action have drug codes beginning with a “c” and are followed by their respective Multum therapeutic category code. RXDDRGID is missing for don’t know (99999) RXDDRUG entries.

Therapeutic class codes associated with a drug are found in a separate data release file, RXQ_DRUG.

There are two files related to the prescription drug data. The contents of each file are described below. The files can be linked by the variable RXDDRGID.

The file named C_RXQ_RX contains data on all survey participants 3 to 15 years of age and their use of a prescription drug. Participants who reported the use of multiple prescription drugs will have multiple records, that is, a record for each drug.

The file named RXQ_DRUG contains therapeutic drug class information on all drugs reported by NNYFS participants in 2012 and NHANES participants from 1988–1994 through 2011–2012. It contains drug (up to 4) and ingredient (up to 6) therapeutic category codes for each drug. It also has a variable that identifies if the drug is made up of a single or multiple ingredients.

C_RXQ_RX: Participant's Use of Prescription Drug(s)

Variable Name	Label
SEQN	Respondent sequence number
RXDUSE	Taken prescription medicine, past month
RXDDRUG	Generic drug name
RXDDRGID	Generic drug code
RXQSEEN	Medicine container seen by interviewer
RXDDAYS	Number of days taken medicine
RXDCOUNT	Number of prescription medicines taken

RXQ_DRUG: Drug Information

Variable Name	Label
RXDDRGID	Generic drug code
RXDDRUG	Generic drug name
RXDINGFL	SINGLE/MULTIPLE INGREDIENT DRUG
RXDDCI1A	DRUG CATEGORY ID - CATEGORY 1, LEVEL 1
RXDDCI1B	DRUG CATEGORY ID - CATEGORY 1, LEVEL 2
RXDDCI1C	DRUG CATEGORY ID - CATEGORY 1, LEVEL 3
RXDDCI2A	DRUG CATEGORY ID - CATEGORY 2, LEVEL 1
RXDDCI2B	DRUG CATEGORY ID - CATEGORY 2, LEVEL 2
RXDDCI2C	DRUG CATEGORY ID - CATEGORY 2, LEVEL 3
RXDDCI3A	DRUG CATEGORY ID - CATEGORY 3, LEVEL 1
RXDDCI3B	DRUG CATEGORY ID - CATEGORY 3, LEVEL 2
RXDDCI3C	DRUG CATEGORY ID - CATEGORY 3, LEVEL 3
RXDDCI4A	DRUG CATEGORY ID - CATEGORY 4, LEVEL 1
RXDDCI4B	DRUG CATEGORY ID - CATEGORY 4, LEVEL 2
RXDDCI4C	DRUG CATEGORY ID - CATEGORY 4, LEVEL 3
RXDDCN1A	DRUG CATEGORY NAME - CATEGORY 1, LEVEL 1
RXDDCN1B	DRUG CATEGORY NAME - CATEGORY 1, LEVEL 2
RXDDCN1C	DRUG CATEGORY NAME - CATEGORY 1, LEVEL 3
RXDDCN2A	DRUG CATEGORY NAME - CATEGORY 2, LEVEL 1
RXDDCN2B	DRUG CATEGORY NAME - CATEGORY 2, LEVEL 2
RXDDCN2C	DRUG CATEGORY NAME - CATEGORY 2, LEVEL 3
RXDDCN3A	DRUG CATEGORY NAME - CATEGORY 3, LEVEL 1
RXDDCN3B	DRUG CATEGORY NAME - CATEGORY 3, LEVEL 2
RXDDCN3C	DRUG CATEGORY NAME - CATEGORY 3, LEVEL 3
RXDDCN4A	DRUG CATEGORY NAME - CATEGORY 4, LEVEL 1
RXDDCN4B	DRUG CATEGORY NAME - CATEGORY 4, LEVEL 2
RXDDCN4C	DRUG CATEGORY NAME - CATEGORY 4, LEVEL 3
RXDICI1A	INGREDIENT CATEGORY ID - CATEGORY 1, LEVEL 1
RXDICI1B	INGREDIENT CATEGORY ID - CATEGORY 1, LEVEL 2
RXDICI1C	INGREDIENT CATEGORY ID - CATEGORY 1, LEVEL 3
RXDICI2A	INGREDIENT CATEGORY ID - CATEGORY 2, LEVEL 1
RXDICI2B	INGREDIENT CATEGORY ID - CATEGORY 2, LEVEL 2
RXDICI2C	INGREDIENT CATEGORY ID - CATEGORY 2, LEVEL 3
RXDICI3A	INGREDIENT CATEGORY ID - CATEGORY 3, LEVEL 1
RXDICI3B	INGREDIENT CATEGORY ID - CATEGORY 3, LEVEL 2
RXDICI3C	INGREDIENT CATEGORY ID - CATEGORY 3, LEVEL 3
RXDICI4A	INGREDIENT CATEGORY ID - CATEGORY 4, LEVEL 1
RXDICI4B	INGREDIENT CATEGORY ID - CATEGORY 4, LEVEL 2
RXDICI4C	INGREDIENT CATEGORY ID - CATEGORY 4, LEVEL 3
RXDICI5A	INGREDIENT CATEGORY ID - CATEGORY 5, LEVEL 1
RXDICI5B	INGREDIENT CATEGORY ID - CATEGORY 5, LEVEL 2
RXDICI5C	INGREDIENT CATEGORY ID - CATEGORY 5, LEVEL 3
RXDICI6A	INGREDIENT CATEGORY ID - CATEGORY 6, LEVEL 1
RXDICI6B	INGREDIENT CATEGORY ID - CATEGORY 6, LEVEL 2
RXDICI6C	INGREDIENT CATEGORY ID - CATEGORY 6, LEVEL 3
RXDICN1A	INGREDIENT CATEGORY NAME - CATEGORY 1, LEVEL 1
RXDICN1B	INGREDIENT CATEGORY NAME - CATEGORY 1, LEVEL 2
RXDICN1C	INGREDIENT CATEGORY NAME - CATEGORY 1, LEVEL 3
RXDICN2A	INGREDIENT CATEGORY NAME - CATEGORY 2, LEVEL 1
RXDICN2B	INGREDIENT CATEGORY NAME - CATEGORY 2, LEVEL 2
RXDICN2C	INGREDIENT CATEGORY NAME - CATEGORY 2, LEVEL 3
RXDICN3A	INGREDIENT CATEGORY NAME - CATEGORY 3, LEVEL 1
RXDICN3B	INGREDIENT CATEGORY NAME - CATEGORY 3, LEVEL 2
RXDICN3C	INGREDIENT CATEGORY NAME - CATEGORY 3, LEVEL 3
RXDICN4A	INGREDIENT CATEGORY NAME - CATEGORY 4, LEVEL 1
RXDICN4B	INGREDIENT CATEGORY NAME - CATEGORY 4, LEVEL 2
RXDICN4C	INGREDIENT CATEGORY NAME - CATEGORY 4, LEVEL 3
RXDICN5A	INGREDIENT CATEGORY NAME - CATEGORY 5, LEVEL 1
RXDICN5B	INGREDIENT CATEGORY NAME - CATEGORY 5, LEVEL 2
RXDICN5C	INGREDIENT CATEGORY NAME - CATEGORY 5, LEVEL 3
RXDICN6A	INGREDIENT CATEGORY NAME - CATEGORY 6, LEVEL 1
RXDICN6B	INGREDIENT CATEGORY NAME - CATEGORY 6, LEVEL 2
RXDICN6C	INGREDIENT CATEGORY NAME - CATEGORY 6, LEVEL 3

Analytic Notes

The variable RXDCOUNT provides a count of all prescription products reported in the prescription medication section adjusting for products moved into or out of the final file. The count includes products reported as “don’t know” by participants who reported they had taken a prescription medication but did not know the name of the medication. However, prescription supplements in the Dietary Supplements File are not included in the total count. Therefore, this variable does not provide a comprehensive count of all prescription products used by the survey participants.

In some cases it may appear as though participants reported the same prescription drug more than once. That is, the same generic ingredient name and product code may be listed more than once. There are a several reasons for these duplications. Participants may have reported different brand name medications which had the same generic ingredient name, the medications may have been different forms or dosages of the same product (e.g., Albuterol “oral tablet” vs. “inhalation solution”), or the participant may have reported different lengths of use or reasons for use of the products.

During the data editing process, outlier values were examined. When there was insufficient information to conclude that values were invalid, they were left in the data set. Analysts should examine the distribution of the data and consider whether or not it is appropriate to include or exclude extreme values in a given analysis.

Respondent sequence number (SEQN) in the prescription medication data is not a unique identifier. Participants who reported the use of multiple prescription drugs will have multiple records, that is, a record for each drug. Analysts should convert a drug level data to a personal level data, that is, a record for each person, before merging it with NHANES/NNYFS demographic and other data files by using SEQN.

Please refer to the NHANES Analytic Guidelines for further details on the use of sample weights and other analytic issues.

Codebook and Frequencies